Xilio Therapeutics, Inc. (XLO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98422T2096
Xilio Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 43.77 m USD |
| Operating income | -41.98 m USD |
| EBIT | -35.04 m USD |
| Net income | -35.04 m USD |
| Diluted EPS – continuing operations | -4.19 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
More stocks
- Oriental Food Industries Hold (7107.KL)
- PMW International Bhd (0379.KL)
- Ai Energy Public Company Limited (AIE.BK)
- Santierul Naval Orsova SA (SNO.RO)
- INIFY Laboratories AB (INIFY.OL)
- Canyon Resources Ltd (CAY.AX)
- Vuno Inc. (338220.KQ)
- Hankook Furniture Co. Ltd (004590.KQ)
- Denali Bancorporation Inc (DENI)
- TRIO-TECH INTERNATIONAL (TRT)
- TJ media Co. Ltd (032540.KQ)
- Boundless Bio, Inc. (BOLD)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.